Drugs /

ganitumab

Back to Drugs List
Associated Genetic Biomarkers

Overview

Generic Name(s):
ganitumab
NCI Definition [1]:
A recombinant, fully human monoclonal antibody directed against the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity. Ganitumab binds to membrane-bound IGF-1R, preventing binding of the ligand IGF-1 and the subsequent triggering of the PI3K/Akt signaling pathway; inhibition of this survival signaling pathway may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis. IGF-1R is a tyrosine kinase and a member of the insulin receptor family. IGF-1R activation stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF-1R signaling has been highly implicated in tumorigenesis and metastasis.

Clinical Trials

View Clinical Trials for ganitumab

Ganitumab has been investigated in 4 clinical trials, of which 4 are open and 0 are closed. Of the trials investigating ganitumab, 1 is early phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 1 is phase 2 (1 open), and 1 is phase 3 (1 open).

EWSR1 Fusion and FUS Fusion are the most frequent biomarker inclusion criteria for ganitumab clinical trials.

Ewing sarcoma/peripheral primitive neuroectodermal tumor, alveolar rhabdomyosarcoma, and embryonal rhabdomyosarcoma are the most common diseases being investigated in ganitumab clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Ganitumab
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating ganitumab and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
amg-479, amg 479, ganitumab, anti-igf-1r fully human monoclonal antibody amg-479, anti-igf-1r human monoclonal antibody amg-479
Drug Categories [2]:
Therapeutic antibodies
NCIT ID [1]:
C71531

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.